<DOC>
	<DOCNO>NCT02222870</DOCNO>
	<brief_summary>The study evaluate safety immunogenicity 2014-2015 formulation Fluzone Quadrivalent vaccine , administer 1- 2-dose schedule , accordance Advisory Committee Immunization Practices ( ACIP ) recommendation , child 6 month &lt; 9 year age . Objective : - To describe safety 2014-2015 formulation Fluzone Quadrivalent vaccine , administer 1- 2-dose schedule , accordance ACIP recommendation , child 6 month &lt; 9 year age . Observational objective : - To describe immunogenicity 2014-2015 formulation Fluzone Quadrivalent vaccine , administer 1- 2-dose schedule accordance ACIP recommendation , child 6 month &lt; 9 year age . - To submit available serum subject Center Biologics Evaluation Research ( CBER ) analysis WHO , Centers Disease Control Prevention ( CDC ) , Food Drug Administration ( FDA ) support formulation recommendation subsequent influenza vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent , Influenza Vaccine</brief_title>
	<detailed_description>Participants assign appropriate age group base age time enrollment . Participants receive dose Fluzone Quadrivalent vaccine , 2 dos influenza vaccine recommend per ACIP guidance , receive second dose Visit 2 ( 28 day Visit 1 ) . Solicited adverse event ( AE ) information collect 7 day vaccination , unsolicited AE information collect Visit 1 Visit 2 , Visit 3 subject receive 2 dos . Serious adverse event ( SAE ) information collect study . Immunogenicity evaluate participant prior vaccination Day 28 final vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject 6 month &lt; 9 year age day first study vaccination ( study product administration ) Subject parent/legally acceptable representative willing able attend schedule visit comply study procedure entire duration study . Assent form sign dated subject 7 &lt; 9 year age , informed consent form sign dated parent ( ) another legally acceptable representative subject 6 month &lt; 9 year age . For subject 6 month &lt; 12 month age , bear full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg ( 5.5 lb ) . Known systemic hypersensitivity egg , chicken protein , vaccine component , history lifethreatening reaction Fluzone Quadrivalent vaccine vaccine contain substance ( complete list vaccine component include Prescribing Information ) . History serious adverse reaction influenza vaccine . Receipt vaccine within 30 day receive study vaccine , plan receive another vaccine Visit 2 subject receive 1 dose influenza vaccine Visit 3 subject receive 2 dos influenza vaccine . Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 30 day precede first study vaccination course study unless intervention study occur within 30 day prior first study vaccination none plan subject would complete safety surveillance present study . Prior vaccination formulation 20142015 influenza vaccine . Bleeding disorder receipt anticoagulants 3 week precede inclusion , may contraindication intramuscular vaccination , discretion Investigator . Thrombocytopenia , may contraindication intramuscular vaccination , discretion Investigator . Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine . Personal history GuillainBarré Syndrome . Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) . Personal history clinically significant developmental delay ( discretion Investigator ) , neurologic disorder , seizure disorder . Chronic illness , opinion Investigator , stage might interfere trial conduct completion . Known seropositivity human immunodeficiency virus , hepatitis B , hepatitis C. Moderate severe acute illness/infection ( accord Investigator judgment ) day vaccination febrile illness ( temperature ≥ 100.4°F ) . A prospective subject include study condition resolve febrile event subside . Receipt immune globulin , blood , bloodderived product past 3 month . Identified natural adopt child Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza virus vaccine</keyword>
	<keyword>Quadrivalent Influenza Virus Vaccine ( No Preservative )</keyword>
	<keyword>Fluzone®</keyword>
</DOC>